Details for Patent: 8,273,341

Title:	Antiviral compounds
Abstract:	The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Inventor(s):	Guo; Hongyan (Foster City, CA), Kato; Darryl (Foster City, CA), Kirschberg; Thorsten A. (Foster City, CA), Liu; Hongtao (Foster City, CA), Link; John O. (Foster City, CA), Mitchell; Michael L. (Foster City, CA), Parrish; Jay P. (Foster City, CA), Graupe; Michael (Foster City, CA), Sun; Jianyu (Foster City, CA), Taylor; James (Foster City, CA), Bacon; Elizabeth M. (Foster City, CA), Canales; Eda (Foster City, CA), Cho; Aesop (Foster City, CA), Kim; Choung U. (Foster City, CA), Cottell; Jeromy J. (Foster City, CA), Desai; Manoj C. (Foster City, CA), Halcomb; Randall L. (Foster City, CA), Krygowski; Evan S. (Foster City, CA), Lazerwith; Scott E. (Foster City, CA), Liu; Qi (Foster City, CA), Mackman; Richard (Foster City, CA), Pyun; Hyung-Jun (Foster Cit, CA), Saugier; Joseph H. (Foster City, CA), Trenkle; James D. (Foster City, CA), Tse; Winston C. (Foster City, CA), Vivian; Randall W. (Foster City, CA), Schroeder; Scott D. (Foster City, CA), Watkins; William J. (Foster City, CA), Xu; Lianhong (Foster City, CA)
Assignee:	Gilead Sciences, Inc. (Foster City, CA)
Filing Date:	Nov 08, 2011
Application Number:	13/291,977
Claims:	1. A method of inhibiting HCV in a human comprising administering a compound of formula: ##STR01307## wherein: V is alkyl; L is benzimidazolyl; M is a 5-membered heteroaryl ring; A.sup.15 is: ##STR01308## and P is selected from: ##STR01309## or a pharmaceutically acceptable salt, or prodrug thereof to the human. 2. The method of claim 1 wherein the compound is a compound of formula: ##STR01310## or a pharmaceutically acceptable salt or prodrug thereof . 3. The method of claim 1 wherein the compound is a compound of formula: ##STR01311## or a pharmaceutically acceptable salt or prodrug thereof. 4. The method compound of claim 1 wherein P is selected from: ##STR01312## 5. The method of claim 1 wherein P is ##STR01313## 6. The method of claim 1 wherein P is ##STR01314## 7. The method of claim 1 wherein the compound is a compound of formula: ##STR01315## or a pharmaceutically acceptable salt or prodrug thereof. 8. The method of claim 1 wherein the compound is a compound of formula: ##STR01316## or a pharmaceutically acceptable salt or prodrug thereof. 9. The method of claim 1 wherein the compound is a compound of formula: ##STR01317## wherein: V is alkyl; M is a 5-membered heteroaryl ring; and A.sup.15 is: ##STR01318## or a pharmaceutically acceptable salt or prodrug thereof. 10. The method of claim 1 wherein the compound is a compound of formula: ##STR01319## wherein: V is alkyl; and A.sup.15 is: ##STR01320## or a pharmaceutically acceptable salt or prodrug thereof. 11. The method of claim 1 wherein each V is: ##STR01321## 12. The method of claim 1 wherein the compound is a compound of formula: ##STR01322## or ##STR01323## or a pharmaceutically acceptable salt or prodrug thereof. 13. The method of claim 1 wherein the compound is a compound of formula: ##STR01324## or a pharmaceutically acceptable salt or prodrug thereof. 14. The method of claim 1, further comprising administering at least one additional therapeutic agent. 15. The method of claim 14, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. 16. The method of claim 14, wherein said additional therapeutic agent is a nucleoside analogue. 17. The method of claim 16, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine. 18. The method of claim 13, further comprising administering at least one additional therapeutic agent. 19. The method of claim 18, wherein said additional therapeutic agent is selected from the group consisting of ribavirin analogs, NS3 protease inhibitors, NS5b polymerase inhibitors, alpha-glucosidase 1 inhibitors, hepatoprotectants, non-nucleoside inhibitors of HCV, and other drugs for treating HCV. 20. The method of claim 18, wherein said additional therapeutic agent is a nucleoside analogue. 21. The method of claim 20, wherein said nucleoside analogue is selected from ribavirin, viramidine, levovirin, an L-nucleoside, and isatoribine.